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Abstract
ALK positive diffuse large B-cell lymphomas (DLBCL) are a distinct lymphoma subtype associated with a poor outcome. Most
of them feature a t(2;17) encoding a clathrin (CLTC)-ALK fusion protein. The contribution of deregulated ALK-activity in the
pathogenesis and maintenance of these DLBCLs is not yet known. We established and characterized the first CLTC-ALK
positive DLBCL cell line (LM1). LM1 formed tumors in NOD-SCID mice. The selective ALK inhibitor NVP-TAE684 inhibited
growth of LM1 cells in vitro at nanomolar concentrations. NVP-TAE684 repressed ALK-activated signalling pathways and
induced apoptosis of LM1 DLBCL cells. Inhibition of ALK-activity resulted in sustained tumor regression in the
xenotransplant tumor model. These data indicate a role of CLTC-ALK in the maintenance of the malignant phenotype
thereby providing a rationale therapeutic target for these otherwise refractory tumors.
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Introduction
Expression of anaplastic lymphoma kinase (ALK) fusion
proteins resulting from chromosomal translocations involving
chromosome band 2p23 is a hallmark of anaplastic large cell
lymphomas (ALCL) [1]. The most frequently detected ALCL
translocation t(2;5) encodes a nucleophosmin (NPM)-ALK fusion
protein with constitutive tyrosine kinase activity which is clearly
implicated in the pathogenesis of ALCL [2,3].
Diffuse large B cell lymphomas (DLBCL) harbouring ALK
fusion proteins were first described in 1997 [4]. With few
exceptions these ALK-translocated DLBCLs display a fine
granular cytoplasmic ALK-staining characteristic for the fusion
of clathrin (CLTC) with ALK caused by the reciprocal
translocation t(2;17)(p23;q23) [5,6,7]. These DLBCLs are further
characterized by the expression of immunoglobulin light chain
kappa or lambda, plasma cell associated antigens CD38 and
CD138, and epithelial membrane antigen (EMA), but lack
expression of CD30 antigen and many other B- and T-cell
markers [4,6,7]. From the published case reports based on
approximately 50 patients, these lymphomas seem to be associated
with a poor outcome in children and adults compared to both
ALK-positive ALCL and ALK-negative DLBCL when treated
with current chemotherapy regimens [8,9].
Small molecule inhibitors of the ALK kinase have recently been
developed [9,10]. However, their therapeutic potential in ALK
positive DLBCL has not been studied so far in part due to the lack
of representative preclinical models. We report the characteriza-
tion of the first CTLC-ALK positive DLBCL cell line (LM1), the
establishment of a pre-clinical model to study the role of CLTC-
ALK activity in DLBCL lymphomagenesis, and demonstrate that
these lymphomas display activation of ALK signalling pathways
and are potently suppressed in vitro and in vivo by a selective ALK
inhibitor.
Materials and Methods
Ethics Statement
The tissue donor was included in a protocol approved by the
Institutional Review Board of the Justus-Liebig University in
1999 that included the use of biopsy material for further
biological studies. In accordance, the parents of the patient gave
a written informed consent that included the use of tumor
material and normal bone marrow for cell banking as well as for
the establishment of the tumor cell line and use of the cells for
further studies. Procedures involving animals followed National
Institutes of Health guidelines and were approved by and done
according to guidelines of the Animal Institute Committee of the
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18436Weill Cornell College of Medicine (Antitumor Assessment Core
Facility of Sloan-Kettering Institute, specific protocol ID
0803732-A).
Cell lines and chemicals
The DLBCL cell lines Karpas422 and LM1, the ALCL cell
lines SUDHL1 and Karpas299 and the BL cell line DG75 were
grown in medium containing 90% RPMI and 10% FCS
supplemented with antibiotics, L-glutamine and HEPES. The cell
lines Karpas422, Karpas299, SUDHL1 and DG75 were obtained
from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen (DSMZ) repository that performs authentication
based on a battery of appropriate test procedures including
immunotyping and genotyping. Cells were maintained in these
conditions during the experiments and NVP-TAE684 (hereon
TAE-684) was added from a concentrated DMSO stock solution
to the 10% serum-containing culture medium. The ALK-inhibitor
TAE-684 (CID16038120) was synthesized in N. Gray’s laboratory
[10].
Reverse transcriptase polymerase chain reaction (RT-PCR)
and sequencing
Total RNA was extracted from cell lines or frozen tumor
material with Trizol reagent according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). cDNA synthesis was
performed with 1 mg of total RNA, random hexamers or oligo-
dT and Superscript-II/III reverse transcriptase (Invitrogen).
Reverse Transcriptase (RT)-PCR conditions and primers were
previously described [11]. Additional primers are shown in Table
S1. In experiments involving TAE-684, LM1 cells were treated
with DMSO or TAE-684 10 nM for 12 h and the RNA isolated
using RNeasy Plus kit (Qiagen) following the manufacturer
instructions. cDNA was synthesized using High Capacity RNA-
to-cDNA kit (Applied Biosystems). We amplified specific genes
using the Fast SYBR Green conditions (initial step of 20 sec at
95 C followed by 40 cycles of 1 sec at 95 C and 20 sec at 60 C).
The CT value of the housekeeping gene (RPL13A) was subtracted
from the correspondent genes of interest (DCT). The standard
deviation of the difference was calculated from the standard
deviation of the CT values (duplicates). Then, the DCT values of
the TAE-684-treated cells were expressed relative to their
respective DMSO-treated cells using the DDCT method. The
folds of expression for each gene in cells treated with the drug
relative to control treated cells is determined by the expression:
2
2DDCT. Results were represented as fold of expression with the
standard error of the mean (SEM) for 2 series of duplicates. The
CLTC-ALK specific RT-PCR fragment from frozen tumor at the
time point of relapse was cloned in the PCR 2.1 TOPO vector
(Invitrogen). Sequencing analysis of the CLTC-ALK plasmid was
performed on an ABI PRISM 3100 (Applied Biosystems, Foster
City, CA) automated sequencing analyzer using standard
sequencing methods.
Immunoblotting, phospho-array and flow cytometry
Cell lysates were prepared using 50 mM Tris pH 7.4,
150 mM NaCl and 1% NP-40 lysis buffer. Lysates for nuclear
and cytoplasmatic fractions were obtained using a fractionation
kit (Biovision) following the manufacturer’s instructions. Protein
concentrations were determined using the BCA kit (Pierce). Fifty
micrograms of protein lysates were resolved by SDS-PAGE,
transferred to nitrocellulose membrane, and probed with the
indicated specific primary antibodies: rabbit to Akt (Cell
Signaling), rabbit to STAT3 (Cell Signaling), rabbit to p44/
p42 MAPK (Cell Signaling), mouse anti RPS6 (Cell Signaling),
rabbit anti phosphorylated Akt (Ser473) (Cell Signaling), rabbit
anti phosphorylated p44/p42 MAPK (Thr202/Tyr204) (Cell
Signaling), rabbit anti phosphorylated RPS6 (Ser235/236) (Cell
Signaling), rabbit anti phosphorylated STAT3 (Tyr750) (Cell
Signaling) and mouse to Alk (BD Bioscience, San Jose, CA).
Membranes were then incubated with a peroxidase-conjugated
correspondent secondary antibody. Detection was performed
using an ECL detection system. Relative levels of protein
phosphorylation in LM1 cells treated with DMSO or TAE-684
10 nM for 24 h were determined using a phospho-array
(Proteome Profiler Array ARY003, R&D Systems, Inc.,
Minneapolis, MN) following the manufacturer instructions.
The scanned film image was analyzed using the ImageJ
freeware (NIH, Bethesda, MD). The spot density of the proteins
of interest was normalized using the spot density of the positive
controls. A detailed protocol and localization of the proteins in
the array can be accessed in http://www.rndsystems.com/pdf/
ary003.pdf. Flow cytometry was performed with a BD
FACSCalibur (BD Bioscience, San Jose, CA) using CD30-FITC
and CD45-APC antibodies for surface staining and ALK-PE for
intracellular staining. All antibodies were from BD Bioscience
(San Jose, CA).
IGHV mutation analysis
IGHV mutation analysis was performed by multiplex PCR
using the BIOMED2 protocol. Sequences were compared with
published germ line VH, D, and JH genes using the International
ImMunoGeneTics (IMGT) database (http://www.imgt.org) Mu-
tational status was calculated as percent deviation from the closest
matching germ line VH segment.
Single nucleotide polymorphism (SNP) array analysis
The Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa
Clara, CA) has been used according to the protocol provided by
the manufacturer (Affymetrix). Microarrays were washed and
stained with the Fluidics Station 450 (Affymetrix) and scanned
with the GeneChip Scanner 3000 (Affymetrix) using the
Command Console software (Affymetrix). The Birdseed v2
algorithm was used to genotype tumor samples. Copy number
analysis, loss of heterozygosity analysis and segmentation was
calculated using Genotyping Console software version 3.0.2
(Affymetrix).
Growth inhibition determination
Cell lines were grown at their respective concentration that were
sufficient to keep the untreated cells in exponential growth over
the 48 h drug exposure time. We determined cell viability by using
a fluorometric resazurin reduction method (CellTiter-Blue,
Promega, Madison, WI) following the manufacturer’s instructions.
The fluorescence (560Ex/590Em) was determined using the
Synergy4 microplate reader (Biotek Inc, Winooski, VT). Fluores-
cence was determined for six replicates per treatment condition or
controls. We normalized cell viability in TAE-684-treated cells to
their respective controls (DMSO). We used CompuSyn software
(Biosoft, Great Shelford, Cambridge, UK) to plot the dose-effect
curves and to determine the concentration of drug that inhibits
50% the growth of cell lines compared to control treated cells
(GI50).
Activated STAT DNA binding assay. The DNA-binding
capacity of STAT3 and STAT5a was assayed by plate-based assay
(TransAM, Active Motif, Carlsbad, CA) following the
manufacturer instructions. Briefly, 5610
6 LM1 and Karpas422
cells were treated with TAE-684 10 nM or DMSO control for 4 h.
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adsorbed STAT consensus oligonucleotides (59-TTCCCGGAA-
39). For control treated cells the assay was performed in the
absence or presence of 20 pmol of competitor oligonucleotides
that contains either a wild-type or mutated STAT consensus
binding site. Interferon-treated HeLa cells (5 mg per well) were
used as positive controls for the assay. After incubation and
washing, rabbit polyclonal anti-STAT5a or anti-STAT3
antibodies (1:1000, Active Motif) were added to each well,
followed by HPR-anti-rabbit secondary antibody (1:1000, Active
Motif). After HRP substrate addition, absorbance was read at
450 nm with a reference wavelength of 655 nm (Synergy4, Biotek,
Winooski, VT). In this assay the absorbance is directly
proportional to the quantity of DNA-bound transcription factor
present in the sample. Experiments were carried out in triplicates.
Results were expressed as arbitrary units (AU) from the mean
absorbance values (450/655) with SEM.
Cell-Cycle-Analysis
Exponentially growing LM1 and Karpas299 cells were
incubated with 10 nM TAE-684 or DMSO for 4, 12 and 24 h.
Cells were fixed with 70% ethanol and incubated for 2 h at 4uC.
After washing with ice cold PBS the cells were incubated with
50 mg/ml RNAse A and 50 mg/ml propidium iodide at 37uC for
30 m. Cell cycle distribution was analyzed with a FACS-Calibur
flow cytometer (BD Bioscience, San Jose, CA).
Detection of apoptotic cell with Annexin-V
Distribution of apoptotic, death and viable cells were deter-
mined by using Annexin-V-PE Apoptosis detection Kit I
according to the manufacturers instructions (BD Bioscience, San
Jose, CA). Briefly, 4610
5 proliferating LM1 and Karpas299 cells
were treated with DMSO or 10 nM TAE684 for 24 h After
washing with PBS, cells were stained with Annexin-V-PE and 7-
AAD at RT for 15 m. Cells were analysed on a FACS-Calibur
with Cell Quest Pro software (BD Biosciences, San Jose, CA).
Caspase-7 and -3 activity
The activity of caspase-7 and caspase-3 was determined using
the Apo-ONE caspase 3/7 assay (Promega). Cell lines were treated
with TAE-684 10 nM or control for 4 h followed by 1 h exposure
to the pro-fluorescent Z-DEVD-R110 substrate. Activation of Z-
DEVD-R110 by the activity of caspases 3 and 7 allows the R110
group to become intensely fluorescent (Exitation499 nm/
Emission521 nm), which was measured using the Synergy4 micro-
plate reader in four replicates. Caspase-7 and -3 activity was
related to the cell number determined by CellTiter-Blue (Promega)
in a multiplex assay. Results are expressed in relative fluorescent
units (RFU) normalized to cell number.
Cell proliferation
LM1 cell proliferation was determined by measuring incorpora-
tion of the nucleoside analog 5-ethynyl-29-deoxyuridine (EdU) into
newly synthesized DNA following the manufacturer instructions
(Click-iT EdU, Invitrogen) with modification for suspension cells.
LM1 cells were treated with DMSO or TAE-684 5, 10 and 20 nM
for 1 h following incubation with EdU reagent for additional 23 h.
Experiment was carried out in 4 replicates. EdU incorporation was
measured by the abundance of a fluorescent product (Amplex
UltraRed reagent, Invitrogen) and normalized to the viable cellular
number determined by dye exclusion (ethidium bromide and
orange G staining, easycount, Immunicom).
Mice xenotransplant models
Six to eight-week old male SCID and NOD-SCID mice were
purchased from the National Cancer Institute (Bethesda, MA) or
from Charles River Laboratories International Inc, (Wilmington,
MA). Mice were subcutaneously injected in the left flank with low-
passage human LM1 and Karpas422 DLBCL cells. Tumor
volume was monitored every other day using electronic digital
calipers (Fisher Scientific, Hamptom, NH) in two dimensions.
Tumor volume was calculated using the formula: Tumor Volume
(mm
3)=(smallest diameter
26largest diameter)/2. When tumors
reached a palpable size (approximately 75 to 100 mm
3), the mice
were randomly assigned to different treatment arms; in conse-
quence these experiments were all performed once tumors had
fully formed in the animals. TAE-684 was dissolved in vehicle
(10% pyrrolidinone, 90% PEG300, both reagents from Sigma,
Saint Louis, MO) and administered by oral gavage. Mice were
weighed twice a week. All mice were euthanized by cervical
dislocation under anesthesia when at least 2/10 tumors reached
15 mm in any dimension that for the cell lines used corresponded
approximately to 5 weeks. Directly after euthanasia, all organs and
tissues underwent careful macroscopic and microscopic (hema-
toxylin-eosin staining) examination for signs of toxicity.
Immunohistochemistry
Slides were stained using standard procedures using Envison
reagents (Dako, Glostrup Denmark) following the manufacturer
instructions. Microscopic pictures were acquired using a final 400-
X magnification with an Axioscope 40 microscope (Zeiss, Jena,
Germany) corresponding to a 0.5 mm picture diameter at room
temperature with a Color Vision 3 camera (Soft Imaging Systems,
Mu ¨nster, Germany). Pictures were adjusted in respect of sharpness
and brightness using Adobe Photoshop 5.0 software (Adobe
Systems Inc, San Jose, CA).
Results
Establishment of the CLTC-ALK positive DLBCL cell line
LM1
The cell line LM1 was established from the bone marrow of a
13 year-old girl suffering from a systemic relapse of a CLTC-ALK-
positive DLBCL. The patient initially presented with a rapidly
growing cervical and supraclavicular mass. Histopathological
evaluation demonstrated large ALK-positive lymphoma cells
suggestive of anaplastic large cell lymphoma of T- or 0-lineage
(ALCL) and treatment was initiated accordingly [12]. The patient
progressed locally after the first course of chemotherapy and an
additional biopsy was taken. Revision of the histology of the initial
biopsy as well as analysis of the second biopsy revealed the
presence of ALK-positive DLBCL with expression of CD138,
VS38c, CD38 and EMA, fine granular cytoplasmic ALK-staining
and expression of the immunoglobulin kappa light chain as well as
gamma heavy chain (Figure 1). Negativity for CD30, T cell
markers (CD5, CD5, CD43, CD56, CD2, granzyme B) as well as
CD20 and CD79a further confirmed the diagnosis. Molecular
cytogenetics as well as RT-PCR for CLTC-ALK transcripts
revealed t(2;17) (p23;q23) with expression of CLTC-ALK in the
cells of the relapsed tumor (Figure 2A).
Despite subsequent intensive chemotherapy, the lymphoma
progressed again locally. Highly intensive chemotherapy with
autologous stem cell rescue and concomitant local radiotherapy
was then administered, resulting in complete remission. This was
followed by allogeneic blood stem cell transplantation. However,
the patient relapsed 53 days later both locally and in the bone
marrow. The infiltrating lymphoma cells were positive for CLTC-
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kept under in vitro culture conditions using RPMI supplemented
with penicillin/streptomycin, 4 mM L-glutamine and 20% fetal
calf serum in a humidified incubator at 37uC with 5% CO2.
We determined the ability of these cells to propagate in vitro and
whether they maintained the phenotype of the parental tumor.
The immunophenotype of the cells in culture (from hereon named
‘‘LM1 cells’’) was confirmed to be the same as the primary tumor:
The cells expressed CD138, VS38c, CD38 and EMA, showed fine
granular cytoplasmic ALK-staining and expression of the
immunoglobulin kappa light chain as well as gamma heavy chain
(Figure 1) Like the primary tumors, LM1 cells were negative for
CD30, T cell markers, CD20 and CD79a (Figure 1 and not
shown). The expression of the CLTC-ALK fusion could be
demonstrated by RT-PCR in both the primary tumor and in the
LM1 cell line (Figure 2A). Sequencing analysis indicated the
presence of the CLTC-ALK fusion transcript (Figure 2B).
Immunoblot analysis with an Alk1 antibody showed exclusive
cytoplasmic expressed protein of the expected molecular weight
for CLTC-ALK (Figure 2C). The cell line carried a productively
rearranged IGH sequence with a heavily mutated IGHV4-4 gene
and a germline identity of only 86,61%.
The complex near-tetraploid karyotype of the cell line was:
74,91,4n.,XXXX,del(1)(p10p35),t(2;17)(p23;q23)x2,add(2)(p11),
der(4)t(4;15)(p14;q15),add(7)(q34,35)x2,der(9)t(9;13)(q24;q12)x2,add(17)
(p11)x2,inc[cp 15]. SNP analysis of mononuclear cells from the patient
bone marrow and the established LM1 cell line detected a number of
changes associated to the cell line including chromosomal gain in 1q,
3q13.31-qtel, 8, 11p13 and 19p as well as chromosomal loss in 1p,
2q22.1-qtel, 4q12-qtel, 7q36.3, 10, 13q11-q21.32, 13q21.33-q22.2,
17ptel-13p13.1, 17q22, 19q, and Xp21.1-q21.31, Xq21.33-q22.1,
Xq22.3-qtel. No regions of partial uniparental disomy were identified
(Figure 2D and Table S2). Moreover, 94.7% of the SNPs were
identically called in the bone marrow normal mononuclear cells and in
the derived cell line which, considering that imbalances reduce the
numbers of identical calls, strongly supports the identity of the cell line.
LM1 forms tumors in immunocompromised mice
To determine the ability of LM1 to grow in vivo, 1610
7 or
2610
7 cells were subcutaneously injected in the left flank of 10
SCID (5 per cell dosage) and 10 NOD-SCID (5 per cell dosage)
mice. Between 16 and 28 days after the implantation, 3/10 and
9/10 mice grew tumors in the SCID and NOD-SCID back-
ground, respectively. The NOD-SCID mouse was considered the
most appropriate host and 1610
7 cells were xenografted in
subsequent experiments. We evaluated the characteristics of the
LM1 tumor mass comparing them to the primary tumor as well as
to the LM1 cell line. In concordance with the original tumor and
the LM1 cell line, the LM1 xenograft revealed the presence of
plasmoblastic DLBCL with expression of fine granular cytoplas-
mic ALK-staining, expression of the immunoglobulin kappa light
chain, CD138 and negativity for CD30 (Figure 1), indicating that
the cellular features were maintained in the xenografted tumor.
Taken together, these data suggest that the LM1 cell line is an
adequate model to study the biology and therapeutic targeting of
ALK fusion positive DLBCL.
ALK kinase inhibition induces cell death in LM1 cells in
vitro
The selective ALK inhibitor TAE-684 was shown to have
activity against NPM-ALK positive ALCL cell lines in vitro and in
vivo [10]. In order to determine whether an ALK inhibitor also had
activity in CLTC-ALK positive DLBCL, we exposed LM1 cells to
increasing concentrations of TAE-684. The NPM-ALK positive
ALCL cell lines Karpas299 and SUDHL1 were used as positive
controls [10] while the ALK negative DLBCL cell line Karpas422
served as negative control. In agreement with previous publica-
tions [10], SUDHL1 and Karpas299 were susceptible to TAE-684
(GI50 of 21.5 and 30.8 nM respectively) while Karpas422 was
resistant (Figure 3A). TAE-684 inhibited the growth of LM1 at
low nanomolar concentrations (GI50: 8.5 nM) (Figure 3A).
To further characterize the biological effects of ALK inhibition
on the growth and survival of the LM1 cell line, we performed
proliferation, cell cycle and apoptosis analysis on cells treated with
either TAE-684 or DMSO control. LM1 cells were treated with
increasing concentrations of TAE-684 (DMSO, 5, 10 and 20 nM)
for 24 h and assessed for proliferation by a nucleoside analog
(EdU) DNA incorporation assay. Treatment with TAE-684
decreased the EdU incorporation in LM1 cells (Fig. 3B)
indicating that exposure to TAE-684 inhibited proliferation. Since
different NPM-ALK positive ALCL cell lines have been reported
to respond differentially with either apoptosis or G1-cell cycle
arrest [10], we wished to determined whether the effect on
proliferation was due to preferential cell cycle arrest, cell death or
a combination of both. We analyzed cell cycle distribution by flow
cytometry DNA deconvolution at 4, 12 and 24 h after treatment.
TAE-684 10 nM caused G1 cell cycle arrest at 24 h in Karpas299
cells but not in LM1 (Figure S1). There was no cell cycle arrest in
LM1 at any of time points analyzed, suggesting that cell death is
the main mechanism for growth inhibition in this cell line.
Accordingly, TAE-684 exposure for 24 h induced apoptosis in a
dose-dependent manner in LM1 cells as detected by Annexin-V
staining (Figure 3C) and caspase-7 and -3 activation (Figure 3D).
Apoptosis induction was morphologically confirmed with ethidium
bromide and orange G staining under fluorescence microscopy.
Collectively, these data suggest that inhibition of ALK kinase
activity by TAE-684 reduces the growth of LM1 cells by
preferentially inducing apoptosis.
TAE-684 inhibits signalling downstream of CLTC-ALK
Fusions of ALK have oncogenic potential as its aberrant kinase
activity enhances cell proliferation and survival [3]. Similarly to
most normal and oncogenic tyrosine kinases, ALK fusions activate
many interconnected and redundant pathways. The most relevant
and characterized pathways are the ERK, JAK-STAT3 and
PI3K-AKT pathways [3,13]. To determine what pathways are
preferentially affected with TAE-684 in LM1 cells, we performed a
phosphoprotein array in these cells treated with DMSO and TAE-
684 at 10 nM for 24 h. The most affected protein in the array was
STAT3 (Figure 4A and Figure S2). STAT3 phosphorylation in
tyrosine 705 decreases 5 fold after TAE-684 (Figure 4A).
Additional proteins with significant decreases were: p70S6K
T389
(3.2 fold), STAT1
Y701 (2.6 fold), FAK
Y397 (2.4 fold), LCK
Y394 (2
Figure 1. Immunophenotyping analysis of the original lymphoma and the derived cell line LM1. A: Determination (from top to bottom)
of ALK, CD138, CD30 and Ig kappa chain expression and distribution by immunohistochemistry in the original tumor (left column), LM1 cell line
grown in vitro (middle column) and LM1 xenografted tumor in NOD-SCID mice (right column). B: The expression of CD30 (left column) and ALK (right
column) were determined by flow cytometry in the LM1 cell line before and after engraftment in the NOD-SCID mouse model. The ALCL cell line SU-
DHL1 was used as positive control for CD30 and ALK expression while the BL cell line DG75 served as negative control.
doi:10.1371/journal.pone.0018436.g001
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Y699 (2 fold) (Figure 4A and Figure S2).
There were more modest reductions in the phosphorylation of
other proteins such as p90RSK, ERK1/2, AKT, c-JUN, STAT1,
STAT2 and several members of the SRC family (LYN, HCK,
FYN, FRG) among others. We validated some of these changes in
an independent experiment using immunoblots (Figure 4B). In
Figure 2. Genetic characterization of the LM1 cell line. A: The presence of the CLTC-ALK translocation in the patient’s lymph node (LN), bone
marrow infiltrating tumor cells (BM) and the established cell line (LM1) was determined with RT-PCR. The ALCL cell line SU-DHL1 was used as positive
control for the NPM-ALK translocation. The BL cell line DG75 was used as negative control for both translocations involving ALK. ABL was used as
loading control. B: Sequencing analysis indicated the presence of the CLTC-ALK fusion transcript in the LM1 cell line. C: Western blot for ALK showing
exclusive cytoplasmic localization in the LM1 cell line corresponding to the expected molecular weight of the ALK-CLCT fusion protein. SU-DHL1
showed nuclear and cytosolic localization of Alk1 secondary to the NPM-ALK translocation. DG75 was used as negative control. D: SNP profiling of the
LM1 cell line. Gains and losses are indicated in blue and red, respectively. Due to the nearly tetraploid chromosome status of this cell line the single
loss of one copy in 2q22.1-qtel not detected by the software was determined manually (light red).
doi:10.1371/journal.pone.0018436.g002
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following TAE-684 treatment, we found a decrease in phospho-
RPS6
S235/S236, a protein not included in the array (Figure 4B). In
contrast to STAT3 [3], the role of STAT5 in ALK fusion-
mediated lymphomagenesis is more controversial. [3,14]. To
determine whether STAT3 or STAT5 signalling are functional in
CLTC-ALK in DLBCL, we performed DNA binding assays on
lysates of LM1 and Karpas422 cells treated with DMSO or TAE-
684 10 nM for 4 h. In concordance with the protein levels, the
baseline activity of STAT3 was higher in LM1 compared to
Figure 3. In vitro effect of the ALK inhibitor TAE-684. A: The cell lines SU-DHL1 (ALCL), Karpas299 (ALCL) and LM1 (DLBCL) harboring ALK
translocations and the cell line Karpas422 (as negative control) were exposed in six replicates to 8 concentrations (from 1 to 400 nM) of the ALK
inhibitor TAE-684 or vehicle control (DMSO) for 48 h and analyzed for viability. Dose-response curves were plotted. The X-axis shows the dose of TAE-
684 in nM. The Y-axis shows the effect of TAE-684 as compared to vehicle control on cell viability. The experiment was done in triplicates. The
goodness of fit for the experimental data to the median-effect equation (linear correlation coefficient) obtained from the logarithmic form of this
equation was equal or higher than 0.90 for each curve. The concentration of TAE-684 that inhibits 50% the growth of cell lines compared to control
treated cells (GI50) is shown in parentheses. B: Cell proliferation determined by EdU incorporation in DMSO- and TAE-684-treated cells (X-axis,
concentration in nM). Results are expressed as percentage to control after normalization to viable cells. C: Apoptosis in LM1 cells measured by
Annexin-V (and 7-AAD for nuclear staining) after incubation with DMSO or TAE-684 10 nM for 24 h (one representative of triplicate experiments is
shown). D: Caspase-3 and -7 activity in LM1 cells determined after 24 h of exposure to DMSO- or TAE-684- at several concentration (X-axis). Results
are expressed in relative fluorescent units (Y-axis) normalized to cell number.
doi:10.1371/journal.pone.0018436.g003
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DNA binding capacity, whereas the DNA-binding of STAT5 was
only slightly higher in LM1 compared to Karpas422 (Figure 4C).
After 4 h of treatment with TAE-684 10 nM, STAT3 activity
levels decreased significantly (37.161.8 AU to 20.961 AU,
p,0.001) in LM1 cells, but not in Karpas442 cells (8.261.6 AU
to 7.561.2 AU) (Figure 4C). In contrast, the activity of STAT5
did not change significantly after TAE-684 in either cell line
(Figure 4C). The impact of CLTC-ALK inhibition on the cellular
transcriptional activity was determined by the mRNA abundance
of several target genes related to these pathways. In LM1 cells
treated with TAE-684 10 nM for 12 h, we found a decrease in
FOSL2, JUNB, CDC25A, CCND1, CCND2, CCND3, BCL2
and MYC (Figure 4D) transcript abundance. Other target genes
related to these pathways (BCL2L2, MCL1, CDKN1A, FOS,
FOSB, FOSL1, JUN and JUND) did not change significantly
under the experimental conditions (data not shown). The changes
in the CLTC-ALK related pathways with TAE-684 treatment,
including those in phosphoprotein levels and mRNA abundance,
are summarized in Figure 4E. Taken together, our data suggest
that constitutive ALK activity of CLTC-ALK fusion proteins
induces similar survival and proliferative signalling cascades in
DLBCL as NPM-ALK in ALCL.
TAE-684 induces complete regression of LM1 xenografts
In order to evaluate the anti-lymphoma activity of TAE-684 in
vivo, the LM1 cell line was injected into the right flank of 10 NOD-
SCID mice and allowed to form tumors. Once palpable tumors
were detected, pairs of mice were randomized to receive either
TAE-684 10 mg/kg/day 5 days per week for 2 weeks (n=5) or
vehicle (n=5). The drug and vehicle were administered by oral
gavage. The ALK fusion negative DLBCL cell line Karpas422 was
also implanted in NOD-SCID mice (n=10) and treated in the
same way. TAE-684 induced regression of the LM1 tumors by the
second week and complete remission by the third week
(Figure 5A). Remission was sustained without recurrence of
tumors in any of the animals for 13 additional weeks after which
the experiment was terminated and the animals sacrificed
(Figure 5A). In contrast, Karpas422 xenografted tumors were
unaffected by the drug and grew at the same rate as vehicle
controls (Figure 5B). In both models, macroscopic and
microscopic examination of the animals showed no signs of
disease or organ toxicity. The adjusted body weight between
treated and controls were similar for Karpas422 and LM1 animals
(Figure 5C).
Discussion
Here we describe the establishment of the first CLTC-ALK
positive DLBCL cell line from the bone marrow of a patient with
chemotherapy-resistant lymphoma. This cell line, LM1, carries the
same phenotypic and genotypic characteristics as the malignant
cells from the subject. LM1 forms tumors in mice with a similar
growth pattern compared to other established mouse xenograft
models of human DLBCL. LM1 can thus serve as pre-clinical
testing platform for the role of CLTC-ALK in lymphomagenesis
and developing molecular targeted therapy approaches for CLTC-
ALK positive DLBCL.
Our data gained from pharmacological inhibition of ALK-
activity in vitro and in vivo suggest that CLTC-ALK mediates
DLBCL lymphomagenesis and maintenance by constitutive ALK
kinase activity. This observation is in line with data indicating that
CLTC-ALK transforms fibroblasts as efficiently as other ALK-
fusion proteins [15]. Additionally, our data lend further support to
the notion that ALK-fusion proteins confer high oncogenic
potential to transformed cells of different origin independently of
the fusion partner and induce both B- and T-cell lymphomas in
transgenic mice [3,16].
Several small molecule kinase inhibitors have been developed
blocking ALK-kinase activity and signal transduction in a
concentration-dependent manner [10,18,19]. This development
opens the possibility of targeted therapy for ALK-positive
malignancies. Patients with ALK-positive ALCL have a good
overall survival due, in part, to effective relapse strategies including
immunotherapeutic approaches [17,18]. In contrast to ALCL, the
available reports suggest that ALK-positive DLBCL is often a
chemorefractory disease associated with a poorer outcome [8,9].
These patients might, therefore, be candidates for clinical trials
with ALK-inhibitors. The high in vitro and in vivo sensitivity of LM1
cells to ALK inhibition supports the rationale testing these
compounds for ALK-positive DLBCLs.
NPM-ALK-positive cells show activation of signaling path-
ways, such as Src kinases [19], PI3K-AKT [20], ERK [21] and
STAT3 and 5 [13,14,22]. Functional studies suggest a pivotal
role of STAT3 and the PI3K-AKT pathway in NPM-ALK
mediated lymphomagenesis whereas a role for STAT5 is more
controversial [13,14,22]. While ectopic expression of CLTC-
ALK in fibroblasts induced less STAT3 phosphorylation than
other ALK-fusion proteins [15], a recent immunohistological
study detected ubiquitous STAT3 hyperphosphorylation in two
CLTC-ALK positive DLBCL cases compared to ALK negative
DLBCL [23]. In our study CLTC-ALK positive DLBCL cells
exhibited constitutive STAT3 activity as well as activation of Akt
and ERK. Inhibition of ALK-activity decreased the activity of
these three signaling pathways in LM1 cells suggesting that
CLTC-ALK employs similar signaling cascades than NPM-
ALK.
Taken together, our data demonstrate that LM1 is a bona fide
model of the DLBCL subtype featuring the CLTC-ALK
translocation and indicate that growth of CLTC-ALK positive
DLBCL is dependent on ALK kinase. Patients diagnosed with
ALK positive DLBCL may, therefore, be candidates for
therapeutic trials of ALK inhibitors. The incorporation of ALK
status determination into the histopathological characterization of
DLBCL could help identifying these patients more readily.
Figure 4. TAE-684 inhibits signalling downstream of CLTC-ALK in LM1 cells. A: Phosphoprotein abundance in LM1 cells treated with DMSO
(D) or TAE-684 10 nM for 4 h (T). The heat map represent the relative abundance normalized by the positive control in the proteome array (see also
Supp. Fig. 2). The particular protein residue phosphorylated is shown as superscript. B: Western blot for phospho-ALK, ALK, phospho-ERK1, ERK1,
phospho-RPS6, RPS6, phospho-STAT3 and STAT3 in cytosol lysates of LM1 cells treated with DMSO or TAE-684 10 nM for 4 h. C: STAT 3 and STAT5
DNA binding activity (Y-axis, arbitrary units, AU) in Karpas422 and LM1 cells treated with DMSO (representing the baseline activity) and after 4 h of
exposure to 10 nM of TAE-684. Experiments represent duplicates with SEM. D: Transcript abundance for FOSL2, JUNB, CDC25A, CCND1, CCND2,
CCND3, BCL2 and MYC in LM1 cells treated with DMSO (control) or TAE-684 10 nM for 12 h. Data was normalized to RPL13A levels. Data is presented
as fold decrease compared to control (DMSO treated cells). E: Signaling pathways modified in LM1 cells by treatment with TAE-684. Phosphoproteins
(transcripts are represented bellow the double dotted line) with significant decreases by TAE-684 are shown in green boxes, with no changes in
yellow boxes and those not determined in white boxes.
doi:10.1371/journal.pone.0018436.g004
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Figure S1 Cell cycle analysis. LM1 and Karpas299 (positive
control) cells were assessed for cell cycle distribution by propidium iodide
staining and flow cytometry after treatment with TAE-684 10 nM or
DMSO for 24 h. One representative experiment from triplicates is shown.
(TIF)
Figure S2 Phosphoprotein array. Scanned image of the
phosphoprotein array in LM1 cells treated with DMSO (left) or
TAE-684 10 nM for 4 h (right). Certain proteins of interest with
the correspondent phosphorilated residue are identified. A
complete map of the array can be found at http://www.
rndsystems.com/pdf/ary003.pdf
(TIF)
Figure 5. Effect of the ALK inhibitor TAE-684 on the growth of LM1 and Karpas422 xenografts. A: Tumor growth plot in LM1 xenografted
mice treated with vehicle (blue circles) or TAE-684 at 10 mg/kg/day 5 days per week for 2 weeks (red circles). The mice were followed without
treatment until the tumors reached 1500 mm
3 when the mice were killed (beginning of week 5). The treated mice were followed without further
treatment for a total of 16 weeks when they were also killed. The treated mice had no macro or microscopic evidence of tumor relapse. The Y-axis
indicates tumor volume (in mm
3) and X-axis days of treatment. B: The same experiment as in panel A but using Karpas422 mice. In this case all the
mice were killed when the tumors reached 1500 mm
3 (at the end of week 5). C: Adjusted body weight at week 5 in the Karpas422 and LM1 mice for
the control and TAE-684-treated animals. The error bars represent the SEM.
doi:10.1371/journal.pone.0018436.g005
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(TIF)
Table S2 Chromosomal gains and losses in the LM1 cell
line. Chromosomal gain and losses were determined by SNP
array. The cytoband and linear position (bp) are in accordance to
the NCBI Build 36.1.
(TIF)
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